Show simple item record

dc.contributor.authorLaich, A
dc.contributor.authorPatel, H
dc.contributor.authorZarantonello, A
dc.contributor.authorSim, R B
dc.contributor.authorInal, J M
dc.date.accessioned2023-09-15T16:45:02Z
dc.date.available2023-09-15T16:45:02Z
dc.date.issued2022-05-31
dc.identifier.citationLaich , A , Patel , H , Zarantonello , A , Sim , R B & Inal , J M 2022 , ' C2 by-pass: Cross-talk between the complement classical and alternative pathways ' , Immunobiology , vol. 227 , no. 3 , 152225 . https://doi.org/10.1016/j.imbio.2022.152225
dc.identifier.issn0171-2985
dc.identifier.urihttp://hdl.handle.net/2299/26676
dc.description© 2022 Elsevier GmbH. All rights reserved. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.imbio.2022.152225
dc.description.abstractSeveral disorders associated with the total or partial absence of components of the human complement system are known. Deficiencies of classical pathway (CP) components are generally linked to systemic lupus erythematosus (SLE) or SLE-like syndromes. However, only approximately one-third of patients who lack C2 show mild symptoms of SLE. The relatively high frequency of homozygous C2 deficiency without or with minor disease manifestation suggests that there might be a compensatory mechanism which allows the activation of the CP of complement without the absolute requirement of C2. In this study we show that factor B (FB), the C2 homologue of the alternative pathway (AP) of complement, can substitute for C2. This was confirmed by using C4b as immobilised ligand and FB as analyte in Surface Plasmon Resonance (BIACORE). C2 binding to the immobilised C3b-like molecule C3(CH 3NH 2) was not seen. The estimated binding constant for C4bB complex formation was 2.00 * 10 -5 [M]. We were further able to demonstrate that C4b supports the cleavage of Factor B by Factor D. Finally, cleavage of 125I-C3 by C4bBb was evaluated and gave strong evidence that the "hybrid" convertase C4bBb can cleave and activate C3 in vitro. Cleavage activity is very low, but consistent with some of the "C2-bypass" observations of others.en
dc.format.extent9
dc.format.extent4334703
dc.language.isoeng
dc.relation.ispartofImmunobiology
dc.subjectComplement Activation
dc.subjectComplement C2/metabolism
dc.subjectComplement C3/metabolism
dc.subjectComplement C3-C5 Convertases/metabolism
dc.subjectComplement C3b
dc.subjectComplement C4
dc.subjectComplement Factor B
dc.subjectComplement Pathway, Classical
dc.subjectHumans
dc.subjectLupus Erythematosus, Systemic
dc.subjectHuman
dc.subjectComplement
dc.subjectImmunodeficiency diseases
dc.subjectHematology
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.titleC2 by-pass: Cross-talk between the complement classical and alternative pathwaysen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionExtracellular Vesicle Research Unit
dc.contributor.institutionBiosciences Research Group
dc.description.statusPeer reviewed
dc.date.embargoedUntil2023-05-11
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85129928662&partnerID=8YFLogxK
rioxxterms.versionofrecord10.1016/j.imbio.2022.152225
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record